122 related articles for article (PubMed ID: 38890278)
21. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.
Li XL; Zhou J; Chan ZL; Chooi JY; Chen ZR; Chng WJ
Oncotarget; 2015 Nov; 6(34):36689-99. PubMed ID: 26452133
[TBL] [Abstract][Full Text] [Related]
22. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
24. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
Wu X; Lu Y; Qin X
J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
26. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
27. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.
Liu YY; Patwardhan GA; Bhinge K; Gupta V; Gu X; Jazwinski SM
Cancer Res; 2011 Mar; 71(6):2276-85. PubMed ID: 21278235
[TBL] [Abstract][Full Text] [Related]
28. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
29. The low-LET radiation contribution to the tumor dose in diffusing alpha-emitters radiation therapy.
Epstein L; Heger G; Roy A; Gannot I; Kelson I; Arazi L
Med Phys; 2024 Apr; 51(4):3020-3033. PubMed ID: 38096442
[TBL] [Abstract][Full Text] [Related]
30. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
[TBL] [Abstract][Full Text] [Related]
31. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
32. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
33. Functional repair of p53 mutation in colorectal cancer cells using trans-splicing.
He X; Liao J; Liu F; Yan J; Yan J; Shang H; Dou Q; Chang Y; Lin J; Song Y
Oncotarget; 2015 Feb; 6(4):2034-45. PubMed ID: 25576916
[TBL] [Abstract][Full Text] [Related]
34. A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.
Liang Y; Mafuvadze B; Besch-Williford C; Hyder SM
Breast Cancer (Dove Med Press); 2018; 10():53-67. PubMed ID: 29606888
[TBL] [Abstract][Full Text] [Related]
35. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.
Aggarwal M; Saxena R; Sinclair E; Fu Y; Jacobs A; Dyba M; Wang X; Cruz I; Berry D; Kallakury B; Mueller SC; Agostino SD; Blandino G; Avantaggiati ML; Chung FL
Cell Death Differ; 2016 Oct; 23(10):1615-27. PubMed ID: 27258787
[TBL] [Abstract][Full Text] [Related]
36. APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy.
Xie X; Fan C; Luo B; Zhang J; Jensen LD; Burman J; Jönsson C; Ljusberg A; Larsson P; Zhao Z; Sun XF
Mol Cancer Ther; 2023 Aug; 22(8):947-961. PubMed ID: 37216282
[TBL] [Abstract][Full Text] [Related]
37. Modulating Survivin as a Radioresistant Factor, Caspase-3, and Apoptosis by Omega-3 Docosahexaenoic Acid Sensitizes Mutant-p53 Colorectal Cancer Cells to γ-Irradiation.
Hosseini F; Sam MR; Jabbari N; Mozdarani H
Cancer Biother Radiopharm; 2018 Nov; 33(9):387-395. PubMed ID: 30395490
[TBL] [Abstract][Full Text] [Related]
38. Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.
Gurtner K; Kryzmien Z; Koi L; Wang M; Benes CH; Hering S; Willers H; Baumann M; Krause M
Int J Cancer; 2020 Jul; 147(2):472-477. PubMed ID: 31359406
[TBL] [Abstract][Full Text] [Related]
39. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
40. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity.
Lei G; Zhang Y; Hong T; Zhang X; Liu X; Mao C; Yan Y; Koppula P; Cheng W; Sood AK; Liu J; Gan B
Oncogene; 2021 May; 40(20):3533-3547. PubMed ID: 33927351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
